An editorial perspective on the infamous COVID-19 studies retracted by Lancet and NEJM

Over the past 1 month, a story of extreme deceit, data fabrication and publication fraud has emerged from some of the very top journals in medicine. I am certain that by now, most of you have heard about the retracted papers on hydroxychloroquine (HCQ) by Lancet,[1,2] and on cardiovascular disease, drug therapy and mortality related to COVID-19 by the New England Journal of Medicine.[3,4] Incidentally, both these papers were written by the same authors and data were derived from the same international registry, the validity of which could not be confirmed by independent review teams. The paper claiming that HCQ lead to serious cardiovascular side effects caused ripple effects throughout the scientific community,[1] and prompted the World Health Organization (WHO) to temporarily halt recruitment of the international Solidarity trial, evaluating the role of HCQ in COVID-19.[5]

With the retraction, one might believe that justice has been done. However, that is far from the truth. With the retractions, there is still a lot of merit in data-driven recommendations rather than anecdotes and personal experience. I appeal to you to still believe in these fundamentals.

The journey of a research paper from concept to fruition goes through many sieves and faces many checks and balances before it is in print. In these retracted papers, a lot of these balances seem to have been missed. The author’s misconduct of using potentially fabricated data (or at least some of it) notwithstanding, the journal review process missed the fact that the source of the data might be fraudulent. But if you review the published papers carefully, you will notice that everything looks perfectly in place to the naked eye, even to expertly trained eyes of the reviewers who might have reviewed it. The study design looked impeccable, the statistics were good, and the results were expertly presented and discussed beautifully. But the reviewers failed to see the fact that it is next to impossible to have an international registry of the sort mentioned in the paper due to data protection laws, different data formats, de-identification issues and many more hurdles. One must also remember that when the rewards of publishing in the apex journals are huge, the risks taken to commit and then hide misconduct are also huge. The owner of the registry, who was highly likely to have financial interests in publishing such a paper and claim credit and publicity for his database, was the second author in both the Lancet and NEJM papers. Ironically, he has authored papers on ethics and fraud in research himself.[7] It is easy to point these out in retrospect but it is a major lapse on the part of the reviewers to have missed this. But lets face it, most journal editors and reviewers do not ask for the datasheet in 99.99% of cases. However, after this fiasco, this might change. We will now see more and more journals asking authors to submit their datasheets along with their manuscript submissions. For journals who don’t, it may be prudent for the authors to themselves upload their datasheets online repositories such as research gate or research square and mention this in their manuscript cover letters.

Retractions are extremely serious events for any journal and taken very seriously by the editorial board, the parent scientific organization the journal represents, the publisher, and the indexing authorities. At the beginning of the tenure of the current editorial board of the Indian journal of ophthalmology, we had published an editorial on publication ethics covering all these topics including data fabrication, publication fraud, plagiarism and retractions.[8] Most guidelines on retractions are given by the committee of publication ethics (COPE), which state that “editors should consider retracting a publication if they have clear evidence that the findings are unreliable, either as a result of major error (e.g., miscalculation or experimental error), or as a result of fabrication (e.g., of data) or falsification (e.g., image manipulation), it constitutes plagiarism, the findings have previously been published elsewhere without proper attribution to previous sources or disclosure to the editor, permission to republish, or justification (i.e., cases of redundant publication), it contains material or data without authorization for use, copyright has been infringed or there is some other serious legal issue (e.g., libel, privacy), it reports unethical research, it has been published solely based on a compromised or manipulated peer review process, the author(s) failed to disclose a major competing interest (a.k.a. conflict of interest) that, in the view of the editor, would have unduly affected interpretations of the work or recommendations by editors and peer reviewers.[8] The notice of retraction should be published with the link to the retracted paper and with clear reasons for retraction. The retracting authority should also be declared. In the current case, the authors themselves asked for a retraction and furnished an apology which was published online.[2,3] We follow the same guidelines given by the COPE at IJO and the editorial board is ever vigilant so that papers with major deficiencies do not slip through the sieves of our review process.
In conclusion, the past month has possibly witnessed the biggest attempted heist in the history of scientific publications, akin to the Cambridge Analytica fiasco during the American presidential elections in 2016. This attempt at maligning the entire fundamentals of clinical research is worthy of protests and black armbands. But let us not vilify honest attempts at clinical research and data-driven recommendations for patient care, which ultimately supplement your acumen and help you get better results for your patients. Research needs to be meaningful and have clinical applications impacting our practices. Publishing for other motivations might lead you to cut corners and dodge scientific inquiry methods, which is never desirable. When the rewards are large, chances of misconduct are high; hence the editors, reviewers and the readership should have a high index of suspicion to weed these out. The application of clinical research to practice requires you to critically analyze papers, and question its validity before adopting the treatment guidelines.

Before parting, I would like to emphasize that the onus of treating patients is ultimately on us. Let us all tighten up and learn some basic techniques of research so that we can make the best decision for patients and perform the best possible research going forwards.

Sabyasachi Sengupta
Associate Editor, Indian Journal of Ophthalmology, Future Vision Eye Care and Research Centre, Mumbai, Maharashtra, India

Correspondence to: Dr. Sabyasachi Sengupta, Future Vision Eye Care and Research Centre, Mumbai, Maharashtra, India.
E-mail: drsunny1980@gmail.com

References
1. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet 2020. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/abstract. [Last accessed on 2020 Jun 05].
2. Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet 2020. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31324-6/abstract. [Last accessed on 2020 Jun 05].
3. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020. doi: 10.1056/NEJMoa2007621.
4. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19 2020 [retracted in: N Engl J Med 2020 Jun 04]. N Engl J Med. 2020; NEJMoa2007621. doi: 10.1056/NEJMoa2007621.
5. “Solidarity” clinical trial for COVID-19 treatments. Available from: https://www.who.int/emergencies/diseases/novel‑coronavirus‑2019/global‑research‑on‑novel‑coronavirus‑2019‑ncov/solidarity‑clinical‑trial‑for‑covid‑19‑treatments. [Last accessed on 2020 Jun 07].
6. Rubin EJ. Expression of Concern: Mehra MR, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020 doi: 10.1056/NEJMoa2007621.
7. Patel B, Dua A, Koenigsberger T, Desai SS. Combating fraud in medical research: Research validation standards utilized by the journal of surgical radiology. Publications 2013;1:140-5.
8. Sengupta S, Honavar SG. Publication ethics. Indian J Ophthalmol 2017;65:42932.
9. Barbour V, Kleinert E, Wager E, Yentis S. Guidelines for retracting articles. Committee on Publication Ethics; 2009. Available from: https://publicationethics.org/node/19896. [Last accessed 2020 Jun 07].

About the author
Dr. Sabyasachi Sengupta
Dr. Sabyasachi Sengupta is a practicing vitreoretinal surgeon at Future Vision eye care, Mumbai. He is the founder and director of Sengupta’s research academy where he offers courses for training budding researchers on techniques of research methodology. He completed his DNB ophthalmology from Aravind Eye Hospital, Pondicherry and received the Dr G.Venkataswamy gold medal for DNB exam held in December, 2009. He finished his surgical retina training from Sankara Nethralaya and went on to do a post-doc clinical research fellowship at Wilmer Eye Institute, Johns Hopkins. He has received the MacCartney prize from the Royal college of Ophthalmologists for ranking first globally in the ocular pathology section of the FRCOphth fellowship exam, and has the distinction of being the first ever non-British national to receive this award. He has received more than 15 distinguished awards so far. Dr Sengupta has published 90 papers in peer reviewed journals and is a regular invited faculty on research methodology both in India and abroad.